Form 4 for RGNX REGENXBIO Inc.
Accepted 2024-03-07 00:00:00 ET · period of report 2024-03-05 · accession 0001562180-24-002430 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-03-07 | 2024-03-05 | RGNX | PAKOLA STEVE | Chief Medical Off | S - Sale+OE | $28.36 | -12.9K | 107.2K | -11% | -$365.2K |
| DT | 2024-03-07 | 2024-03-05 | RGNX | PAKOLA STEVE | Chief Medical Off | M - OptEx | $22.25 | +12.9K | 120.1K | +12% | +$286.5K |
| DT | 2024-03-07 | 2024-03-05 | RGNX | PAKOLA STEVE | Chief Medical Off | M - OptEx | $0.00 | -12.9K | 31.3K | -29% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-05 | S | D | 12,878 | $28.36 | 107,192 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-05 | M | A | 12,878 | $22.25 | 120,070 | D | — | — | |
| 3 | Derivative | Stock Options (Right to Buy) | 2024-03-05 | M | D | 12,878 | $0.00 | 31,277 | D | $22.25 · — to 2033-01-03 | 12,878 Common Stock | (F2) The previously granted option, representing a right to purchase a total of 44,155 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 3, 2024, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer |